Rituximab 주입관련 부작용발생 및 위험인자 분석
Rituximab Infusion-related Adverse Events and Risk Factors
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: This study aimed to identify the status and risk factors of rituximab infusion-related adverse events (ADE) in rituximab-naïve patients with cancer diseases. Method: A retrospective analysis using electronic medical records review was conducted. Inclusions were patients with a diagnosis of cancer disease with the initiation of rituximabincluded treatment who were naïve to rituximab during January 2011 to March 2013 at National Cancer Center (NCC) in Korea. Result: Total 110 patients, 582 cases of rituximab administrations, were reported in the study. About 57.2% of patients were 51-70 years old and evenly distributed between two genders and 72.7% were BMI less than 25 kg/m2. All of study patients were diagnosed with non-Hodgkin lymphoma. Fifty patients (45.4%) and 54 cases (9.3%) were experienced rituximab infusion-related AEs even with conservative administration protocol at NCC. The most frequently occurring AEs were shivering followed by rash and itching. In single variant analysis, we found that the early stage of NHL, low exposure to rituximab administrations, high white blood cell counts, high lymphocyte counts, high absolute neutrophil count and low lactate dehydrogenase were associated with infusion-related AEs (p<0.05). The early stage of disease, high lymphocyte counts, low exposure to rituximab administrations were also related significantly with AEs in multiple variants analysis (p<0.05). Conclusion: Rituximab infusion-related AEs for patients who were naïve to rituximab were still a concern with conservative administration protocol. The adverse drug reactions were significantly associated with early stage of NHL, higher lymphocyte counts and low exposure to rituximab administrations. The factors need to be considered with close monitoring to prevent rituximab infusion-related AE.
Abstract
Objective: This study aimed to identify the status and risk factors of rituximab infusion-related adverse events (ADE) in rituximab-naïve patients with cancer diseases. Method: A retrospective analysis using electronic medical records review was conducted. Inclusions were patients with a diagnosis of cancer disease with the initiation of rituximabincluded treatment who were naïve to rituximab during January 2011 to March 2013 at National Cancer Center (NCC) in Korea. Result: Total 110 patients, 582 cases of rituximab administrations, were reported in the study. About 57.2% of patients were 51-70 years old and evenly distributed between two genders and 72.7% were BMI less than 25 kg/m2. All of study patients were diagnosed with non-Hodgkin lymphoma. Fifty patients (45.4%) and 54 cases (9.3%) were experienced rituximab infusion-related AEs even with conservative administration protocol at NCC. The most frequently occurring AEs were shivering followed by rash and itching. In single variant analysis, we found that the early stage of NHL, low exposure to rituximab administrations, high white blood cell counts, high lymphocyte counts, high absolute neutrophil count and low lactate dehydrogenase were associated with infusion-related AEs (p<0.05). The early stage of disease, high lymphocyte counts, low exposure to rituximab administrations were also related significantly with AEs in multiple variants analysis (p<0.05). Conclusion: Rituximab infusion-related AEs for patients who were naïve to rituximab were still a concern with conservative administration protocol. The adverse drug reactions were significantly associated with early stage of NHL, higher lymphocyte counts and low exposure to rituximab administrations. The factors need to be considered with close monitoring to prevent rituximab infusion-related AE.
참고문헌 (25)
- Cheson BD, "Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma", The NEJM, 359(6), pp.613~626 (2008)
- "Roche (2012) Mabthera, Roche Products Pty Limited" (2012)[URL]
- Dillman RO, "Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy", Cancer metastasis reviews, 18(4), pp.465~471 (1999)
- Lenz HJ, "Management and preparedness for infusion and hypersensitivity reactions", The oncologist, 12(5), pp.601~609 (2007)
- Institute NC, "Common Terminology Criteria for Adverse Events(CTACE)v4", ~ (2010)
- Kimby E, "Tolerability and safety of rituximab(MabThera)", Cancer treatment reviews, 31(6), pp.456~473 (2005)
- Kang SP, "Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management", The journal of supportive oncology, 5(9), pp.451~457 (2007)
- Czuczman MS, "Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti CD-20 monoclonal antibody and CHOP chemotherapy", J Clin Oncol, 17, pp.268~276 (1999)
- Tuthill M, "Rapid infusion of rituximab over 60 min", Eur J Haematol, 82(4), pp.322~325 (2009)
- Al Zahrani A, "Rapid infusion rituximab changing practice for patient care", J Oncol Pharm Pract, 15(3), pp.183~186 (2009)
- Atmar J, "Review of the safety and feasibility of rapid infusion of rituximab. Journal of oncology practice", American Society of Clinical Oncology, 6(2), pp.91~93 (2010)
- Davis TA, "Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment", Journal of clinical oncology, 18(17), pp.3135~3143 (2000)
- Maloney DG, "IDECC2B8(Rituximab)anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma", Blood, 90(6), pp.2188~2195 (1997)
- Maloney DG, "Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody(IDEC-C2B8)in patients with recurrent B-cell lymphoma", Blood, 84(8), pp.2457~2466 (1994)
- Maloney DG, "IDECC2B8 : results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma", Journal of clinical oncology, 15(10), pp.3266~3274 (1997)
- McLaughlin P, "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma : half of patients respond to a four-dose treatment program", Journal of clinical oncology, 16(8), pp.2825~2833 (1998)
- Piro LD, "Extended Rituximab(anti-CD20 monoclonal antibody)therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma", Annals of oncology, 10(6), pp.655~661 (1999)
- Dillman RO, "Unique aspects of supportive care using monoclonal antibodies in cancer treatment", Supportive cancer therapy, 1(1), pp.38~48 (2003)
- Breslin S, "Cytokine-release syndrome: overview and nursing implications", Clinical journal of oncology nursing, 11(1 Suppl), pp.37~42 (2007)
- Lang DS, "Predictors of acute adverse events from rapid rituximab infusion. Supportive care in cancer", ~ (2013)
- Hong J, "Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma", Supportive care in cancer, 21(4), pp.1145~1152 (2013)
- Byrd JC, "Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance", Journal of clinical oncology, 17(3), pp.791~795 (1999)
- Winkler U, "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8)", Blood, 94(7), pp.2217~2224 (1999)
- Plosker GL, "Rituximab : a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia", Drugs, 63(8), pp.803~843 (2003)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", NEJM, 346(4), pp.235~242 (2002)